Assignee
ALLEGRO PHARMACEUTICALS LLC
US·4 granted patents·7 pending applications·7 citations·filing 2018–2024
Top patents by PatentIndex Score
11 records- 0187US10639347B2Peptides useable for treatment of disorders of the eyeALLEGRO PHARMACEUTICALS LLC·Filed 2019·Granted May 5, 2020·4 cites·16 claims
- 0281US10590166B2Peptides useable for treating cancerALLEGRO PHARMACEUTICALS LLC·Filed 2018·Granted Mar 17, 2020·3 cites·8 claims
- 0371US2024382557A1Inhibition of tumor necrosis factor, pro-inflammatory cytokines and other inflammatory response mediatorsALLEGRO PHARMACEUTICALS LLC·Filed 2024·Application pending·0 cites
- 0467US11666625B2Pharmaceutical compositions and preparations for administration to the eyeALLEGRO PHARMACEUTICALS LLC·Filed 2020·Granted Jun 6, 2023·0 cites·27 claims
- 0565US2022313771A1Inhibition of tumor necrosis factor, pro-inflammatory cytokines and other imflammatory response mediatorsALLEGRO PHARMACEUTICALS LLC·Filed 2022·Application pending·0 cites
- 0664US2020392181A1Peptide compositions and related methodsALLEGRO PHARMACEUTICALS LLC·Filed 2020·Application pending·0 cites
- 0764US2020354402A1Peptide compositions and related methodsALLEGRO PHARMACEUTICALS LLC·Filed 2020·Application pending·0 cites
- 0860US2021085749A1Therapeutic and Neuroprotective PeptidesALLEGRO PHARMACEUTICALS LLC·Filed 2020·Application pending·0 cites
- 0953US2021275624A1Treatments for improving or lessening impairment of mitochondrial functionALLEGRO PHARMACEUTICALS LLC·Filed 2021·Application pending·0 cites
- 1052US2022031800A1Peptides for treating non-exudative macular degeneration and other disorders of the eyeALLEGRO PHARMACEUTICALS LLC·Filed 2020·Application pending·0 cites
- 1149US11673914B2Peptide therapies for reduction of macular thickeningALLEGRO PHARMACEUTICALS LLC·Filed 2020·Granted Jun 13, 2023·0 cites·15 claims
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →